Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma;Prognostische bedeutung der therapiekontrolle durch die positronen-emissions-tomographie mit fluor-18-deoxyglukose bei patienten mit malignen lymphomen

NuklearMedizin

Volumn 40, Issue 1, 2001, Pages 23-30

  Cremerius, U ^a   Fabry, U ^a   Neuerburg, J ^a   Zimny, M ^a   Bares, R ^a   Osieka, R ^a   Bull U ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

FDG; Malignant lymphoma; PET; Prognosis; Residual mass

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY;

EID: 0035110072     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1623988     Document Type: Article

References (33)

1. F-18 fluorodeoxyglucose PET: In vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer
2. Residual mass in lymphoma may not be residual disease
3. Detection of lymphoma in bone marrow by wholebody positron emission tomography
4. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
5. Clinical value of FDG-PE/for therapy monitoring of malignant lymphomas - Results of a retrospective study in 72 patients
6. 18F-FDG to detect residual disease after therapy for malignant lymphoma
7. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma
8. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas
9. Whole-body PET: Physiological and artifactual fluorodeoxyglucose accumulations
10. Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma
11. Whole-body positron emission tomgraphy using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and nonHodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
12. Nonparametric estimation from incomplete observations
13. Gallium-67 imaging: A predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma
14. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: A study with positron emission tomography and fluorine-18-fluorodeoxyglucose
15. Granulation tissue: Pitfall in therapy control with F-18-FDG PET after chemotherapy
16. Extranodal malignant lymphoma: Detection of FDG PET versus CT
17. Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging
18. The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis
19. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease
20. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose
21. A predictive model for aggressive non-Hodgkin's lymphoma
22. Updated Kiel classification for lymphomas
23. The applications of PET in clinical oncology
24. Comparison of findings with 18-FDG-PE/and CT in pretherapeutic staging of malignant lymphoma
25. FDG PET of the retroperitoneum: Normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls
26. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma
27. False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease
28. Functional imaging of Hodgkin's disease with FDG-PE/and gallium67
29. Influence of chemotherapy on FDG uptake by human cancer xenografts in nude mice
30. F-18-FDG positron imaging in oncological patients: Gamma camera coincidence detection versus dedicated PET
31. Dual-head gamma camera 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in oncological patients: Effects of nonniform attenuation correction on lesion detection
32. The role of positron emission tomography (PET) in the management of lymphoma patients